Search research articles
Contact Us
Filters
Showing results (31-40 of 39) with videos related to
Page
of 4
Sort By:
You have reached the last page of results.
This site can display upto 39 results.
Nature Medicine
|
June 6, 2024
Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial
Roger Li, Paras H Shah, Tyler F Stewart, et al.
Nature Medicine
|
June 18, 2024
Author Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial
Roger Li, Paras H Shah, Tyler F Stewart, et al.
Nature Medicine
|
July 2, 2024
Publisher Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial
Roger Li, Paras H Shah, Tyler F Stewart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 30, 2025
TAR-200 for Bacillus Calmette-Guérin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study
Siamak Daneshmand, Michiel S Van der Heijden, Joseph M Jacob, et al.
Urologic Oncology
|
July 30, 2023
First analysis of the safety and efficacy of UGN-101 in the treatment of ureteral tumors
Joseph M Jacob, Solomon L Woldu, Jennifer Linehan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 9, 2025
Erratum: TAR-200 for Bacillus Calmette-Guérin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study
Siamak Daneshmand, Michiel S Van der Heijden, Joseph M Jacob, et al.
Urologic Oncology
|
January 16, 2025
Development of TAR-200: A novel targeted releasing system designed to provide sustained delivery of gemcitabine for patients with bladder cancer
Siamak Daneshmand, Ashish M Kamat, Neal D Shore, et al.
Current Opinion in Urology
|
October 9, 2025
Side effect management and procedural best practices with indwelling intravesical drug-releasing systems in the treatment of bladder cancer: recommendations from expert panels
Benjamin Pradere, Maarten Schuit, Félix Guerrero-Ramos, et al.
European Urology
|
January 22, 2020
Comprehensive Assessment of Immuno-oncology Biomarkers in Adenocarcinoma, Urothelial Carcinoma, and Squamous-cell Carcinoma of the Bladder
Andrea Necchi, Russell Madison, Daniele Raggi, et al.
Page
of 4
Search research articles
Search
Showing results (31-40 of 39) with videos related to
Sort By:
Page
of 4
You have reached the last page of results.
This site can display upto 39 results.
Nature Medicine
|
June 6, 2024
Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial
Roger Li, Paras H Shah, Tyler F Stewart, et al.
Nature Medicine
|
June 18, 2024
Author Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial
Roger Li, Paras H Shah, Tyler F Stewart, et al.
Nature Medicine
|
July 2, 2024
Publisher Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial
Roger Li, Paras H Shah, Tyler F Stewart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 30, 2025
TAR-200 for Bacillus Calmette-Guérin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study
Siamak Daneshmand, Michiel S Van der Heijden, Joseph M Jacob, et al.
Urologic Oncology
|
July 30, 2023
First analysis of the safety and efficacy of UGN-101 in the treatment of ureteral tumors
Joseph M Jacob, Solomon L Woldu, Jennifer Linehan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 9, 2025
Erratum: TAR-200 for Bacillus Calmette-Guérin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study
Siamak Daneshmand, Michiel S Van der Heijden, Joseph M Jacob, et al.
Urologic Oncology
|
January 16, 2025
Development of TAR-200: A novel targeted releasing system designed to provide sustained delivery of gemcitabine for patients with bladder cancer
Siamak Daneshmand, Ashish M Kamat, Neal D Shore, et al.
Current Opinion in Urology
|
October 9, 2025
Side effect management and procedural best practices with indwelling intravesical drug-releasing systems in the treatment of bladder cancer: recommendations from expert panels
Benjamin Pradere, Maarten Schuit, Félix Guerrero-Ramos, et al.
European Urology
|
January 22, 2020
Comprehensive Assessment of Immuno-oncology Biomarkers in Adenocarcinoma, Urothelial Carcinoma, and Squamous-cell Carcinoma of the Bladder
Andrea Necchi, Russell Madison, Daniele Raggi, et al.
Page
of 4